Introduction
Human T-cell leukemia virus type-1 (HTLV-1) is etiologically implicated with the aggressive lethal malignancy adult T-cell leukemia (ATL). 1 Recently studies attribute important roles for the HTLV-1 bZipper protein (HBZ) [2] [3] [4] and the HTLV-1-mediated modulation of cellular microRNAs (miRNAs) expression 5, 6 play important roles in the ATL pathology. However, the multifunctional viral Tax oncoprotein is widely regarded to be the critical factor for initiating the leukemic process leading to ATL. [7] [8] [9] Notably, however, the vast majority of the infected individuals remain asymptomatic carriers since shortly after infection the virus enters into a latent state in which viral gene expression is very low and therefore, the level of Tax is presumably too low for exerting its oncogenic activities. 7, 10 Nevertheless, about 5% of the carriers do eventually develop this malignancy after several decades of latency. On this ground we hypothesize that the transition from latency to the leukemic progression in these particular carriers is triggered by a rare event of a temporary activation of the dormant virus which transiently elevates Tax to its oncogenic threshold that can initiate this process. Moreover, due to the low Tax level in the carriers' infected cells, the activation of the dormant virus could be independent of Tax. In previous studies we have shown that the viral LTR can be activated in absence adult t-cell leukemia (atL) is caused by htLV-I. the viral tax oncoprotein plays a central role in initiating the process to atL. however, after infection htLV-1 enters into latency, during which virus gene expression is very low, so that the level of tax is likely insufficient for exerting its oncogenic activities. therefore only 5% of the infected individuals may develop atL several decades after infection. It is assumed that the transition from latency to atL development requires at least a temporary activation of the latent virus in order to elevate tax to its oncogenic threshold. We have previously found that DNa damaging agents, which usually induce apoptosis, can also activate the viral long terminal repeats (LtR) and that the anti-apoptosis Bcl-2 protein not only inhibits the induction of apoptosis but concomitantly prevents their LtR activation effect. therefore, the present study was designed to identify the factor that while participating in the apoptotic cascade acts also to activate the viral LtR. For this purpose we employed ectopic vectors expressing these apoptotic factors together with potent shRNas against each of them and anti caspase peptide inhibitors. We have found that in addition to its function as initiator of the mitochondrial apoptotic cascade, caspase 9 can acts also as an executer which among other non-apoptotic functions it forms an sp1-p53 complex that activates the LtR by binding to an sp1 recognition site residing in the LtR. this finding can help in designing effective preventing strategies against atL development in clinically latent htLV-1 carriers.
Role of caspase 9 in activation of HTLV-1 LTR expression by DNA damaging agents
of Tax by a variety of DNA damaging and other stress-inducing agents. 11 This finding led us to propose that environmental or intrinsic stress-inducing factors might similarly be involved in activating the LTR of the latent virus and thereby trigger the leukemogenic process in these carriers. We also found that this activation is mediated by binding of an Sp1-p53 complex to an Sp1 recognition site residing within the Ets responsive region 1 (ERR-1) of the LTR. 12 However, since the leukemic ATL cells do not contain Tax or contain low levels of this oncoprotein, it seems likely that the activation of the dormant virus is only temporary and that Tax triggers during this time only the initial leukemic steps, which need to be followed by subsequent events after Tax returns to its latent state. Of note, we have found that all the tested virus-activating stress factors set the cells into apoptosis. 11 Moreover, we have also demonstrated that ectopic expression of the anti-apoptotic Bcl-2 blocks both the apoptosis induction and the LTR activation, 11 indicating that the LTR activation by these agents is strictly linked with the apoptotic cascade. Therefore the aim of the present study was to identify the LTR-activating apoptotic factor. A priori it seemed highly paradoxical to assume that the virus activation by an apoptosis-inducing mechanism might lead to ATL genesis. However, this paradox has been reconciled by our observation that HTLV-1 infected T cells which manifest active viral gene expression, are protected by Tax from provokes the mitochondrial pathway 17 which is initiated by the mitochondrial outer membrane permeabilization (MOMP). MOMP is controlled by members of the Bcl-2 family which includes pro-(e.g., Bax, Bak) and anti-(e.g., Bcl-2, Bcl-x L ) apoptotic factors. [17] [18] [19] Activated Bax and Bak cooperatively form large pores in the mitochondrial outer membrane, which can be avoided by the Bcl-2 protein and certain other anti-apoptotic members of this family by sequestration of Bax and Bak and conversely, the anti-apoptotic factors are inhibited by Bax and Bak. The ultimate effect of this interplay between the anti-and pro-apoptotic Bcl-2 members depends on their quantitative ratio. 13 MOMP leads to a release of cytochrome c (cyt-c) and other pro-apoptotic proteins. Cyt-c and dATP jointly trigger a caspase activation cascade that culminates in apoptosis. Caspases are classified as initiators and effectors. Caspases 9 (casp 9) is initiator in the mitochondrial pathway. Cyt-c and dATP bind in the cytoplasm to an adaptor protein named Apaf-1 and promote formation of the multi-protein apoptosome complex that binds the pro-casp 9. Consequently pro-casp 9 oligomerizes within this complex and is activated by it own auto-cleavage. Casp 2 is also regarded as an initiator in the mitochondrial pathway 20 but it functions by interacting directly with the outer mitochondrial membrane and thereby induces the release of above mentioned pro-apoptotic proteins. 21, 22 Casp 8 and 10 are initiators in the death receptors pathway. In both apoptotic pathways, the respective activated initiator caspases cleave and activate downstream effector caspases (casp 3, 6 and 7), that execute the apoptotic death by cleaving some cytoplasmic and nuclear proteins associated with the cell morphogenesis and vitality. 17, 23, 24 It is important to note that beside their role in apoptosis, caspases are also involved in a wide range of non-apoptotic cellular processes associated with survival, DNA repair, cellular proliferation, differentiation, lipid metabolism and others. [24] [25] [26] Therefore, it should not be surprising that inducing the formation of the Sp1-p53 complex, which activates the viral LTR, might be exerted by one of these caspases' activities.
In an attempt to identify the apoptotic factor involved in the DNA damage-induced LTR activation we dissected the mitochondrial apoptotic cascade and checked the effect of its individual components on the viral LTR expression. Our results suggest that either casp 9 by itself, or one of its activated non-caspase targets, is involved in the formation of the LTR activating Sp1-p53 complex.
Results
Knockdown of casp 2 represses the DNA damage-induced LTR activation. Since casp 2 is the first component of the mitochondrial apoptotic cascade, it was the first to be investigated in this study for its involvement in DNA damage-induced LTR apoptosis induction by such agents, suggesting that Tax protein which emerges in the cells after activation of the dormant virus can protect these cells from apoptosis and enable their subsequent leukemic progression.
There are two major apoptotic pathways; the mitochondrial 13, 14 and the death receptors 15, 16 pathways. DNA damage The mitochondrial outer membrane permeabilization is required for the LTR activation by casp 2. Since casp 2 can act both as initiator or effector, 20 we clarified whether casp 2 directly activated the LTR on its own by acting in this case as an effector or whether this activation was mediated by a downstream factor of the mitochondrial pathway that was triggered by its initiator function. This was done by examining the effect of casp 2 in the presence of Bcl-2. Figure 1B shows that Bcl-2 blocks the LTR activation by the ectopic casp 2, indicating that the LTR activation by the ectopic casp 2 required the induction of MOMP by the initiator function of casp 2.
Bax-induced LTR activation is inhibited by Bcl-2 in a dose dependent manner. Since Bax and Bak are actually the factors that cooperatively execute the MOMP, [17] [18] [19] we examined the effect of ectopic Bax on the LTR expression. This was done by transfecting the cells with LTR-Luc alone, or together with two doses (1 μg and 2 μg) of Bax expressing plasmid. Figure 2A demonstrates that Bax substantially stimulates the LTR expression in a dose dependent manner. Figure 2A shows also that Bcl-2 inhibits this effect of Bax and that the extent of this inhibition depends on the quantitative ratio of these two factors. As expected, Figure 2B shows that anti Bax shRNA blocked the reporter activation by Bax, whereas anti Bcl-2 shRNA abolished the inhibitory effect of Bcl-2 on the Bax-mediated LTR activation.
Cyt-c function is essential for LTR activation by the mitochondria-perturbing factors. Since cyt-c is the first activation. We started this inquiry by examining the effect of its knockdown by specific shRNA. For this study TPA was arbitrarily chosen from a number of DNA damaging agents that we found in earlier studies to concomitantly induce apoptosis and LTR activation. TPA is known to cause DNA damage due to its ability to generate potent superoxides in cells. We have found in those studies that both of the above two effects of TPA were jointly blocked by Bcl-2 11 which, as noted above, is an inhibitor of the mitochondrial membrane permeabilization. [17] [18] [19] Figure 1A illustrates a preliminary protein gel blot analysis that we performed to assess the efficiency of casp 2 shRNA-mediated knockdown, using monoclonal anti human casp 2 antibody (generated in mouse against a 16 amino acid peptide from the N-terminus of casp 2, SigmaAldrich). This was done by transfecting the cell with an equal amount (2 μg) of each of our five purchased plasmids expressing different anti casp 2 shRNA clones (Sigma-Aldrich) and measuring the level of pro-caspase 2 in the whole cell extract at 24 h after transfection. This analysis revealed that all of these clones reduced the level of pro-casp 2 within 24 h by about 80%. To verify the specificity of these clones the blot was stripped from the first antibodies and sequentially reprocessed with antibodies against two irrelevant gene products, p53 and actin. None of these products were affected by any of these shRNA clones (Fig. 1A) .
To assess the involvement of casp 2 in the LTR activation by TPA the cells were exposed to 50 nM TPA for 48 h and then transfected with the LTR-Luc reporter alone or together with plasmids expressing Bcl-2 or anti casp 2 shRNA. Cells without TPA treatment served as controls. Figure 1B shows that Bcl-2 had no effect on the basal LTR-Luc expression in these control cells. In accord with our earlier reports in reference 11, 12 and 27, Figure 1B shows that TPA strongly stimulated the LTR-Luc activity and that Bcl-2 diminished this stimulation, suggesting that TPA activated the LTR through a process involving MOMP. Strikingly, knockdown of casp 2 by one of the abovetested shRNAs also blocked the TPA-induced LTR activation. This finding raised the possibility that TPA promoted casp 2 to activate the LTR.
LTR activation by ectopic casp 2. To substantiate the role of casp 2 in the LTR activation, the cells were transfected with LTR-Luc alone or with plasmid expressing casp 2 ± plasmid expressing anti casp 2 shRNA. In line with reports from other laboratories that overexpressed ectopic casp 2 is functionally active independently of external stimulus, 21, 28 Figure 1B demonstrates that ectopic expression of casp 2 strongly stimulated the LTR-Luc expression. The possibility that this stimulation resulted from some non-specific artifact rather that from casp 2 activity was excluded by showing that this stimulation was prevented by anti casp 2 shRNA. inhibitor blocked LTR activation by TPA, casp 2 and Bax, thus further confirming that the LTR activation by all these agents required the mitochondrial downstream caspase activation cascade.
LTR stimulation requires activation of the initiator casp 9 but not of the effector caspases 3 and 7. Cyt-c acts in the cytoplasm to activate the initiator casp 9, which in turn activates the downstream effector casp 3 and 7. To investigate the role of these caspases the cells were transfected with LTR-Luc alone or together with cyt-c ± specific shRNAs against casp 9, casp 7 or casp 3. Figure 5 indicates that while the LTR activation by cyt-c was profoundly diminished by the anti casp 9 (Fig. 5A) it was unaffected by the shRNAs against casp 7 (Fig. 5B ) and casp 3 (Fig. 5C) . This data seem to suggest that casp 9 alone can activate the LTR. Since casp 7 and casp 3 are functionally related, post-mitochondrial perturbation apoptotic component, we examined its requirement for the LTR activation by the above tested mitochondria perturbing agents. Figure 3A demonstrates that silencing of cyt-c by specific shRNA blocked the LTR activation by TPA, ectopic casp 2 and Bax, indicating that cyt-c was an intermediate factor that mediated the LTR activation by these agents.
LTR is activated by ectopic cyt-c. To further substantiate this role of cyt-c we examined the effect of ectopic cyt-c. For this purpose it was important to check the sub-cellular distribution of the ectopic cys-c protein. This was done by transfecting the cells with flag-tagged cyt-c in order to distinguish it from the endogenous mitochondrial cyt-c. At 24 h after transfection the cells were fractionated to whole cell extract, isolated mitochondria and mitochondria-free cytosol. Aliquots from each fraction, adjusted to represent the same number of cells (5 x 10 5 ), were subjected to protein gel analysis with anti-flag antibody. Figure 3B lane 2 illustrates that most of the flag-cyt-c was retained in the mitochondria-free cytosolic fraction. Our next experiment depicted in Figure 3C demonstrates that both the flag-tagged and the untagged cyt-c proteins equally stimulated the LTR expression and that, as expected, this stimulation was unaffected by Bcl-2, which confirmed that the activity of the cytosol-residing ectopic cyt-c did not depend on the mitochondrial perturbation. However, LTR activation was blocked by anti cyt-c shRNA, thus ruling out the possibility that this activation reflected some artifact unrelated to cyt-c.
The cyt-c-induced LTR activation requires the downstream caspase activation. Next we investigated whether cyt-c directly activates the LTR by its own or indirectly through triggering the downstream caspase cascade. This was done by examining its effect in the presence of the pan-caspase peptide inhibitor z-VAD-fmk, which was added to the cells 1 h before transfection to ensure its presence within the cells before caspase activation. Figure 4 demonstrates that z-VAD-fmk strongly inhibited the cyt-c induced LTR activation. It also demonstrates that this Figure 4 . the z-VaD-fmk pan-caspase peptide inhibitor blocks the cytc-, tpa-, casp 2-and Bax-induced LtR activation. the LtR-Luc plasmid was transfected alone into cells that were pre-treated with tpa for 48 h, or to cells that were co-transfected with cyt-c, casp 2 and Bax. Where indicated, the z-VaD-fmk pan caspase peptide inhibitor was added to the culture 1 hr before transfection to ensure its presence within the cells before caspase activation. the enzymatic activity is described in Figure 1B . section. In the experiment presented in Figure 6A , the cells were transfected with LTR-Luc alone (control) (column 1) or cotransfected with the casp 9 plasmid ± shRNAs against the indicated caspases (columns 2-5). This experiment revealed that casp 9 alone profoundly stimulated the LTR expression (column 2) and that this stimulation was diminished by anti casp 9 shRNA (column 3) but not by shRNAs against casp 3 (column 4) or casp 7 (coloumn 5). Figure 6A also shows that casp 3 (column 6) had no effect on the LTR.
Sp1-p53 complex formation is induced by the ectopic casp 9 but not by ectopic casp 3. Next it was important to assess whether casp 9 could induce the formation of the Sp1-p53 complex which we found earlier to activate the LTR expression by binding to its ERR-1. 12 This was done by reciprocal co-immunoprecipitation analysis of these two components.
it could be argued that activation of either of them by casp 9 is required for the LTR activation. Therefore, knockdown of either of them alone by their specific shRNA is insufficient to block the LTR activation by casp 9. To address this argument both of these two caspases were knocked down together. Figure 5D demonstrates that this double knockdown also did not diminish the casp 9-mediated LTR activation. These shRNAs were also observed to exert the same effects on the LTR activation by TPA, casp 2 and Bax, indicating that only the initiator casp 9, but not effector casp 7 or casp 3, were involved in the LTR activation by these agents.
LTR is activated by ectopic casp 9 but not by ectopic casp 3. To further validate the conclusion from the data shown in Figure  5 , we examined the effect of ectopic expression of the inducible casp 9 and casp 3 as detailed in the "Materials and Methods" 2 and 7-9 ). the specificity of the binding was performed for the nuclear proteins of the casp 9 transfected cells by competition with 50-fold excess of unlabeled w.t. (lane 3) and mutant (lane 4) probes. the proteins bound to the w.t. labeled probe were identified by supershift analysis of the nuclear proteins of the casp-9-transfected cells with anti sp1 and anti p53 antibodies.
Discussion
The HTLV-1 Tax oncoprotein plays a central role in initiation of the process leading to ATL. However, shortly after infection the virus enters into latency, during which the viral gene expression is very low and consequently the Tax level is plausibly insufficient for exerting its oncogenic activities. 7 Therefore, this latency renders the infected individuals asymptomatic seropositive carriers, of whom only a small fraction develop ATL, usually several decades after infection. On this ground we hypothesize that initiation of the oncogenic process requires activation of the latent virus to elevate Tax to its effective threshold. In earlier studies we have noted that DNA-damaging and other stress agents, which usually induce apoptosis, can also activate the expression of HTLV-1 LTR in a variety of human T-cell lines and primary T-lymphocytes. 11 Moreover, our experiments have proven that the LTR activation is strictly dependent on triggering the apoptotic cascade by demonstrating that the anti-apoptosis factor Bcl-2 not only inhibits the induction of apoptosis but concomitantly blocks the LTR activation by the employed DNA-damaging agents. Therefore, we speculate that the LTR of the dormant virus in HTLV-1 carriers might also be activated by external or/and intrinsic DNA-damaging agents. It seems paradoxical to expect that virus activation by agents that concomitantly set the host cells into apoptosis may lead to malignancy. This apparent paradox has been reconciled by our finding that Tax rescues HTLV-1 infected T-cell lines manifesting high viral gene expression from apoptotic death. 11 It is of interest to indicate that Tax can stop the apoptotic cascade at several intermediate stages before cell death by inactivating pro-apoptotic factors while stimulating anti-apoptotic factors. For instance, on one hand Tax functionally inactivates p53 29 which induces apoptosis through activation of casp 2 20, 30, 31 and blocks the function of Bax which is involved in mitochondrial outer membrane permeabilization (MOMP). 32 Tax can also interfere with the functions of caspases 33 and other factors 7 that participate in the apoptotic cascade. On the other hand, Tax activates various anti apoptotic factors like Bcl-2. 34, 35 Therefore, it is reasonable to presume that upon activation of the dormant virus in HTLV-1 carriers by apoptosis-inducing factors, the host cells of the activated virus are set into a race between viral Tax protein accumulation and the progression of apoptosis. Cells in which apoptotic death precedes the optimal Tax accumulation will be eliminated and will not contribute to tumor genesis. However, for cells in which Tax reaches an effective level before their death, Tax will rescue the cells so that they can subsequently continue progression toward a malignant state.
Since Bcl-2 blocks the mitochondrial apoptotic cascade by interfering with the MOMP process, 13, [17] [18] [19] we postulated that a certain component of this cascade might be directly involved in the LTR activation by inducing the formation of the Sp-p53 complex. The present study was designed to identify this component. We started by assessing whether casp 2 is involved in HTLV-1 LTR activation by DNA damaging factors since this caspase is functionally activated by DNA damage and triggers the onset of the apoptotic cascade. 31, 36 We found that knockdown of casp 2 by specific shRNA avoided LTR activation by the DNA Nuclear extracts were derived from the cells at 24 h after their transfection with ectopic casp 9 or casp 3 and from control cells lacking these ectopic caspases. These extracts were analyzed by reciprocal co-immunoprecipitation using mouse anti Sp1 or anti p53 antibodies for the immunoprecipitation step and rabbit anti Sp1 and anti p53 antibodies for the protein gel blot analysis of the co-precipitated proteins. Each immunoprecipitation was performed with 200 μg protein. Figure 6B shows that the precipitate of casp 9-transfected cells, which was pulled down by anti Sp1 antibody, contained both the Sp1 (row 1) and the p53 (row 2) proteins, whereas those of the control and the casp 3-trasnfected cells contained only the Sp1 protein (row 1). Conversely, the precipitate of casp 9-transfected cells, that was pulled down by anti p53 antibody, contained both the Sp1 (row 3) and the p53 (row 4) proteins, whereas those of the control and the casp 3-trasnfected cells contained only the p53 protein (row 4).
Sp1-p53 binding to ERR-1 oligonucleotide is detected only with nuclear extract of casp 9-but not of casp 3-transfected cells. The binding of the Sp1-p53 complex to the ERR-1 sequences was examined by the DNA-protein pull-down assay described in the "Materials and Methods" section using the 3'-biotin-labeled ERR-1 oligonucleotide probe shown in Figure  6C . Figure 6D shows that binding of both the Sp1 and the p53 proteins to this probe could be detected in the nuclear extracts of the casp 9-transfected cells. They could also be found in the extracts of the Bax-and cyt-c transfected cells that served as positive controls. However, they were not detected in the extracts of the casp 3-transfected cells. Since this probe contained an Sp1 site but not a p53 site, the association of p53 to this probe indicated that it was in complex with the Sp1 protein. No such binding of the Sp1-p53 complex was detected when the probe with mutated Sp1 site was employed (data not shown). To further substantiate these data we re-analyzed Sp1-p53 binding to the 3' biotin-labeled ERR-1 probe by electrophoretic mobility shift analysis (EMSA), presented in Figure 6E . While no such binding was detected with the extract of the non-transfected control cells (lane 1), a clear band, designated as band I, was found with the extract of the casp 9-transfected cells (lane 2) but not with the extract of the casp 3-transfected cells (lane 7). The specificity of band I was assessed by showing that it was abolished by 50-fold excess of the unlabeled wild-type (w.t.) probe (lane 3) but not by the unlabeled mutated probe (lane 4). Identification of the proteins included in band I was done by supershift analysis which demonstrated that this band was shifted to position II by an anti Sp1 antibody (lane 5) and to position III by an anti p53 antibody (lane 6). Consistent with our earlier study in reference 12, the anti p53 antibody imposed a substantially stronger supershift than the anti Sp1 antibody. This might indicate that the molar quantity of p53 protein in the Sp1-p53 complex was higher than that of the Sp1 protein, which enabled binding of a higher quantity of the anti p53 antibody to the probe-bound Sp1-p53 complex than that of the anti Sp1 antibody. A similar band at position I was detected with the extract of the Bax-and cyt-c-transfected cells that served as positive controls.
Plasmids and transfection. The reporter plasmid expressing the firefly luciferase (Luc) through HTLV-1 LTR (LTR-Luc) was provided by Susan J. Marriott (Baylor College of Medicine). The plasmid expressing Renilla luciferase via the enhancerless promoter pRL-null (pRL-renilla) was purchased from Promega Corporation. Sets of five plasmids with a Puromycin selection marker, each expressing a different shRNA clone for each of the studied target genes, were purchased from Sigma-Aldrich Corporation. To choose the most appropriate shRNA clones for our experiments their silencing efficiency and specificity were tested by western analysis of their target proteins vs. several randomly selected unrelated proteins. An example for such preliminary analysis is shown in Figure 1A . The plasmid expressing human Bcl-2 through the CMV promoter was provided by Yoseph Shaul (Weizman Institute of Science). The following two plasmids were purchased from Addgene: the plasmid pCEP4-HA-Bax plasmid expressing human Bax, (Addgene plasmid 16587, deposited by Bert Vogelstein and described in ref. 38 ) and the pcDNA3-Casp2-Flag plasmid expressing flag-tagged human casp 2 (Addgene plasmid 11811, deposited by Guy Salvesen, Sanford-Burnham Medical Research Institute). The mechanism of casp 2 activation in response to DNA damage is still not completely clear. 20, 22, 37, [39] [40] [41] Notably, however, unlike most other caspases, transfection of ectopic casp 2 has been shown to induce apoptosis and NFκB activation, indicating that it becomes functionally active in the transfected cells without external signal. 28, 41 Therefore, we could test its effect on the LTR expression directly by conventional transfection analysis. The plasmids expressing flag-tagged and untagged cyt-c were prepared for us by the GeneScript Biology CRO custom service (www.genescript.com). The plasmids expressing inducible casp 9 (iCas-9) and casp 3 (iCas-3) via the promoter of cyclooxygenase-2 (cox-2) gene, were generated in Prof. Godbey's laboratory as previously detailed in reference 42. Cox-2 is expressed in normal cells only in response to specific stimuli, but is constitutively expressed in a wide range of tumor cells 43 including hematopoetic cancer cell lines such as Jurkat. 44, 45 Therefore, genes expressed through cox-2 promoter are selectively expressed only when delivered to such cox-2-expressing cells. Furthermore, appropriate changes were introduced into the iCas-9 and iCas-3 encoding sequences, designed to produce the pro-forms of these caspases which required homodimerization for their activation via autocleavage. This homodimerization could be induced by adding to the culture of the transfected cells, 100 nM AP2107, a component of the ARIAD homodimerizing kit (ARIAD). 42, 46 Transfection of the indicated plasmid combinations was performed by the jetPRIM TM kit (Polyplus transfection, www. polyplus-transfection.com), as directed by the manufacturer, with adjustments to a total of 5 μg DNA per transfection. The transfection efficiency, tested with GFP-expressing plasmid, was found by FACS analysis to range in our employed cells between 70 to 80% (not shown). Each transfection mixture included the pRL-renilla plasmid as an internal control for variation in transfection efficiency. The enzymatic activities were measured at 24 h post-transfection and the Luc activity was normalized to that of renilla and presented as fold of the relevant control. The damaging function of TPA and that ectopic expression of casp 2 substantially activated the LTR independently of DNA damage, thus confirming that the DNA damage-induced LTR activation is mediated by activating the non-active pro-casp 2. Casp 2 was the first caspase to be discovered and it is the most conserved one. However, despite the numerous studies devoted to it, the mechanism of casp 2 activation and its functional activities are still under substantial debate. 36 For example, casp 2 has been shown to function as an initiator of the mitochondrial apoptotic cascade, acting upstream to the mitochondria and inducing MOMP. 17, 20, 21, 36 However, casp 2 has also been noted to act as an executioner which directly interacts with target cellular proteins. 20, 37 To elucidate whether casp 2 affected the LTR by perturbing the mitochondrial membrane we compared its LTR activation to the effect of Bax which is a well-known permeabilizer of the mitochondrial membrane. [17] [18] [19] We found that both agents profoundly activated the LTR and that in both cases this activation was antagonized by Bcl-2, which is a sealer of pores formed in the mitochondrial membrane by the Bax/Bak factors. It is also also a competitive inhibitor of Bax/Bac (see Figs. 1 and 2) .
MOMP leads to a release of cyt-c, which together with dATP participates in activation of casp 9, the initiator of the cascade of the cleavage-mediated activation of the effector caspases 3, 6 and 7. In addition, certain other pro-apoptosis factors are released from the mitochondria. While attempting to find out whether any of these factors was involved in the LTR activation, we found that knockdown of cyt-c abolished LTR activation by TPAinduced DNA damage. LTR activation by casp 2 and by Bax was also diminished by anti cyt-c shRNA, indicating that this factor was essential for the LTR activation by mitochondrialperturbing agents. The question remained whether cyto-c itself could directly activate the LTR if this activation was mediated by a downstream caspase or certain other cellular proteins that might be activated by cyt-c. As an initial step to distinguish between these options we checked the effect of the pan-caspase peptide inhibitor z-VAD-fmk and found that this inhibitor diminished LTR activation by cyto-c, TPA, casp-2 and Bax. Based on these findings we checked the effect of specific anti caspase shRNAs and found that only anti casp 9 shRNA diminished the LTR activation by cyt-c, TPA, casp 2 and Bax (see Fig. 5 ). This finding indicates that casp 9 is the ultimate component of the DNA-damage-induced mitochondrial apoptotic cascade that is involved in the LTR activation by DNA-damaging factors. This conclusion was further supported by an experiment which demonstrated that ectopic expression of casp 9 induced the formation of the Sp1-p53 complex and that this complex binds to the Sp1 recognition site residing within the ERR-1 of the LTR.
Materials and Methods
Cells and culture conditions. This study was performed with the Jurkat human acute lymphocytic leukemia T-cell line. The cells were grown in RPMI-1640 medium supplemented with 10% fetal calf serum, glutamine and antibiotics, and incubated at 37°C in a humid incubator with 5% CO 2 . stranded 3'-biotin-labeled ERR-1 oligonucleotide probe (TAG) (shown in Fig. 6C ) and 10 μg sheared salmon sperm DNA in pull-down buffer (10 mM HEPES, pH 7.9, 25 mM KCl, 500 μM DTT, 2.5% glycerol and protease inhibitor cocktail) and incubated on ice for 90 min. Then Streptavidin-linked agarose beads (70% slurry) were added and the mixtures were gently rotated overnight at 4°C. The beads were then pelleted and washed with cold pull-down buffer. The bound proteins were released from the beads by heating at 95°C for 5 min. Then they were separated by 9% SDS PAGE and identified by protein gel blot analysis with the indicated antibodies.
Electrophoretic mobility shift (EMSA) and supershift assay. Aliquots of 6 μg nuclear proteins of the tested cells were examined for binding to the above-mentioned double stranded 3'-biotin-labeled ERR-1 oligonucleotide probe by mobility shift assay (EMSA) using the LightShift ® Chemiluminescent EMSA kit (PIERCE) as instructed by the supplier. The binding specificity was assessed by competition with 50-fold molar excess of unlabeled mutated and the non-mutated oligonucleotide probe. The bound proteins were identified by supershift with the respective antibodies as instructed by the kit's protocol. 
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plotted results represented the average of triplicate transfections ± SE.
Antibodies. The DO-1 mouse monoclonal antibody which recognizes both the w.t. and mutant p53 configurations and the mouse anti actin antibody, were purchased from Calbiochem and ICN, respectively. Mouse and rabbit antibodies against Sp1, rabbit anti p53 and anti c-Jun, rabbit anti mouse-IgG, mouse anti rabbit-IgG antibodies, were all purchased from Santa Cruz Biotechnology Inc. The indicated antibodies used in our experiments for detecting caspases were purchased from Sigma-Aldrich.
Cell fractionation, co-immunoprecipitation and protein gel blot analyses. Whole cell lysates and subcellular fractions were prepared by NucBuster Kit (Calbiochem, Cat. No. 71183-3) according to the Kit's protocol. For co-immunoprecipitation assays, aliquots of the nuclear extracts (200 μg protein) were immunoprecipitated with the specified mouse antibodies. The precipitates were collected with protein-A/protein-G bound Sepharose beads and washed twice to remove non-specific proteins. Then the bound proteins were dissociated and analyzed by protein gel blot for the co-precipitated proteins with the indicated rabbit antibodies as previously described in reference 11. The specificity of the assay was verified by subjecting the extracts to co-immunoprecipitation with non-specific mouse IgG. For direct western analyses aliquots of the tested extracts (80 μg protein) were analyzed with the respective antibodies as described in reference 47. Equal loading of samples was assessed by stripping the blot from the first antibodies and re-processing it with anti-actin antibody.
Isolation of mitochondria. To assess the subcellular distribution of ectopically expressed cyt-c protein we employed the plasmid expressing the flag-tagged cyt-c and determined its distribution between the mitochondria-free cytosolic fraction and the isolated mitochondria. For this purpose we used the QIAGEN-Qproteome Mitochondia Isolation Kit according to the supplied instructions.
DNA-protein pull-down assay. Nuclear extracts (200 μg protein) of the tested cells were mixed with 6 μg of double
